Exomics and immunogenics

Stéphane Champiat; Charles Ferté; Sophie Lebel‐Binay; Alexander Eggermont; Jean Charles Soria

doi:10.4161/onci.27817

Abstract

Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.

Keywords

MedicineMelanomaCancer researchSomatic cellImmune systemImmunotherapyImmune checkpointImmunologyBiologyGeneticsGene

Affiliated Institutions

Related Publications

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Judith A. Seidel , Atsushi Otsuka , Kenji Kabashima

Melanoma, a skin cancer associated with high mortality rates, is highly radio- and chemotherapy resistant but can also be very immunogenic. These circumstances have led to a rec...

2018 Frontiers in Oncology 1279 citations

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Gang Chen , Alexander C. Huang , Wei Zhang +36 more

Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T ...

2018 Nature 2620 citations

Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

Stephen R. Goding , Kyle Wilson , Ying Xie +7 more

Abstract Recurrent solid malignancies are often refractory to standard therapies. Although adoptive T cell transfer may benefit select individuals, the majority of patients succ...

2013 The Journal of Immunology 204 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube , Alison Klein , Julie R. Brahmer +7 more

Abstract Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide pat...

2014 Clinical Cancer Research 2295 citations

Regulation and Function of the PD-L1 Checkpoint

Chong Sun , Riccardo Mezzadra , Ton N. Schumacher

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immu...

2018 Immunity 2128 citations

Publication Info

Year: 2014
Type: article
Volume: 3
Issue: 1
Pages: e27817-e27817
Citations: 187
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Exomics and immunogenics

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

187

OpenAlex

Cite This

APA Style

                            
                                
                                    Stéphane Champiat, 
                                
                                    Charles Ferté, 
                                
                                    Sophie Lebel‐Binay
                                
                                et al.
                            
                            (2014). 
                            Exomics and immunogenics. 
                            OncoImmunology
                            , 3
                            (1)
                            , e27817-e27817.
                            https://doi.org/10.4161/onci.27817
                        

Identifiers

DOI: 10.4161/onci.27817